Clinical Trials Logo

Mature B-Cell Malignancies clinical trials

View clinical trials related to Mature B-Cell Malignancies.

Filter by:
  • None
  • Page 1

NCT ID: NCT06351527 Not yet recruiting - Clinical trials for Mature B-cell Malignancies

Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ICP-248 in Mature B-cell Malignancies

Start date: April 25, 2024
Phase: Phase 1
Study type: Interventional

Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ICP-248 in Mature B-cell Malignancies

NCT ID: NCT04883957 Active, not recruiting - Clinical trials for Mature B-cell Malignancies

Study of BGB-11417 in Adult Participants With Mature B-cell Malignancies

Start date: July 5, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of BGB-11417 monotherapy, define the maximum tolerated dose (MTD) or maximum administered dose and the recommended Phase 2 dose (RP2D) of BGB-11417 monotherapy for the selected B-cell malignancy dose finding cohorts, and evaluate the safety and tolerability of the ramp-up dosing schedule in the evaluated disease types.

NCT ID: NCT04277637 Recruiting - Clinical trials for Mature B-Cell Malignancies

Study of Bcl-2 Inhibitor BGB-11417 in Participants With Mature B-Cell Malignancies

Start date: March 24, 2020
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safety, tolerability; and to define the maximum tolerated dose (MTD) and Recommended Phase 2 Dose (RP2D); and to evaluate the safety and tolerability of the ramp-up dosing schedule and at the RP2D of BGB-11417 monotherapy, and when given in combination with zanubrutinib and obinutuzumab.

NCT ID: NCT04172246 Active, not recruiting - Clinical trials for Mature B-cell Malignancies

Study of Zanubrutinib in Japanese Participants With B-Cell Malignancies

Start date: January 29, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1/2 study of zanubrutinib in Japanese participants with mature B-cell malignancies. This study intends to assess the use of zanubrutinib as an investigational agent to develop new treatment options for Japanese participants with B-cell malignancies. No formal hypothesis testing will be performed given the small sample size.